Cardiac dysfunction in sepsis: New theories and clinical implications

Intensive Care Medicine

Volumn 24, Issue 4, 1998, Pages 286-295

  Grocott Mason, R M ^a   Shah, A M ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ASSISTED CIRCULATION; CLINICAL TRIAL; CYTOKINE RELEASE; HEART DISEASE; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; META ANALYSIS; MUSCLE CONTRACTION; REVIEW; SEPTIC SHOCK; TACHYCARDIA;

CYTOKINES; HEART DISEASES; HEMODYNAMIC PROCESSES; HUMANS; MYOCARDIAL CONTRACTION; RISK FACTORS; SHOCK, SEPTIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0031945838     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001340050570     Document Type: Review

References (88)

1. Parrillo JE (1993) Pathogenetic mechanisms of septic shock. N Engl J Med 28: 1471-1477
2. Bone RC (1996) Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 24: 163-172
3. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE (1984) Profound hut reversible myocardial depression in patients with septic shock. Ann Intern Med 100: 483-490
4. Ellrodt AG, Riedinger MS, Kimchi A, Berman DS, Maddahi J, Swan HJC, Murata GH (1985) Left ventricular performance in septic shock: reversible segmental and global abnormalities. Am Heart J 110: 402-409
5. Ognibene FP, Parker MM, Natanson C, Shelhamer JH, Parrillo JE (1988) Depressed left ventricular performance; response to volume infusion in patients with sepsis and septic shock. Chest 93: 903-910
6. Natanson C, Danner RL, Fink MP, MacVittie TJ, Walker RI, Conklin JJ, Parrillo JE (1988) Cardiovascular performance with Escherichia coli challenges in a canine model of human sepsis. Am J Physiol 254: H558-H569
7. Parker MM, Suffredini AF, Natanson C, Ognibene FP, Shelhamer JH, Parrillo JE (1989) Responses of left ventricular function in survivors and nonsurvivors of septic shock. J Crit Care 4: 19-25
8. Parker MM, McCarthy KE, Ognibene FP, Parrillo JE (1990) Right ventricular dysfunction of dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest 97: 126-131
9. Poelaert J, Declerck C, Vogelaers D, Colardyn F, Visser CA (1997) Left ventricular systolic and diastolic function in septic shock. Intensive Care Med 23: 553-560
10. Cunnion RE, Schaer GL, Parker MM, Natanson C, Parrillo JE (1986) The coronary circulation in human septic shock. Circulation 73: 637-644
11. Dhainaut J-F, Huyghebaert M-F, Monsallier JF, Lefevre G, Dall'Ava-Santucci J, Brunet F, Villemont D, Carli A, Raichvarg D (1987) Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 75: 533-541
12. Van Lambalgen AA, van Kraats AA, Mulder MF, Teerlink T, van den Bos GC (1994) High energy phosphates in heart, liver, and skeletal muscle of endotoxemic rats. Am J Physiol 266: H1581-H1587
13. Hinshaw LB (1996) Sepsis/septic shock: participation of the microcirculation: an abbreviated review. Crit Care Med 24: 1072-1078
14. Goddard CM, Allard MF, Hogg JC, Walley KR (1996) Myocardial morphometric changes related to decreased contractility after endotoxin. Am J Physiol 270: H1446-H1452
15. Shah AM, Grocott-Mason RM, Pepper CB, Mebazaa A, Henderson AH, Lewis MJ, Paulus WJ (1996) The cardiac endothelium: cardioactive mediators. Prog Cardiovasc Dis 39: 263-284
16. Lefer A, Rovetto M (1970) Influence of a myocardial depressant factor on physiologic properties of cardiac muscle. Proc Soc Exp Biol 134: 269-273
17. Carli A, Auclair MC, Benassayag C, Nunez E (1981) Evidence for an early lipid soluble cardiodepressant factor in rat serum after a sublethal dose of endotoxin. Circ Shock 8: 301-312
18. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W (1985) A circulating myocardial depressant substance in humans with septic shock. J Clin Invest 76: 1539-1553
19. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE (1996) Tumour necrosis factor alpha and interleukin 1 beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 183: 949-958
20. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE (1989) The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321: 280-287
21. Danner RL, Elin RJ, Hoseini JM, Wesley RA, Reilly JM, Parrillo JE (1988) Endotoxemia in human septic shock. Chest 99: 169-175
22. Granton JT, Goddard CM, Allard MF, van Eeden S, Walley KR (1997) Leukocytes and decreased left ventricular contractility during endotoxaemia in rabbits. Am J Respir Crit Care Med 155: 1977-1983
23. Muller-Werdan U, Pfeifer A, Hubner G, Seliger C, Reithmann C, Rupp H, Werdan K (1997) Partial inhibition of protein synthesis by Pseudomonas exotoxin A deranges catecholamine sensitivity of cultured rat heart myocytes. J Mol Cell Cardiol 29: 799-811
24. Kwiatkowska-Patzer B, Patzer JA, Heller LJ (1993) Pseudomonas aeruginosa exotoxin A enhances automaticity and potentiates hypoxic depression of isolated rat hearts. Proc Soc Exp Biol Med 202: 377-383
25. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL (1992) Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257: 387-389
26. 2+]; and contractility in isolated adult rabbit ventricular myocytes. Am J Physiol 271: H1449-H1455
27. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL (1993) Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 92: 2303-2312
28. Liu S, Schreur KD (1995) G protein-mediated suppression of L-type Ca current by interleukin-1 β in cultured rat ventricular myocytes. Am J Physiol 268: C339-C349
29. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ, Zentella A, Albert JD, Shires T, Cerami A (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234: 470-474
30. Natanson C, Eichenholz PW, Danner RL, Eichacker PQ, Hoffman WD, Kuo GC, Banks SM, MacVittie TJ, Parrillo JE (1989) Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 169: 823-832
31. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662-664
32. Kapadia S, Lee J, Torre-Amione G, Birdsall HH, Ma TS, Mann DL (1995) Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 96: 1042-1052
33. de Werra I, Jaccard C, Corradin SB, Chiolero R, Yersin B, Gallati H, Assicot M, Bohuon C, Baumgartner J-D, Glausser MP, Heumann D (1997) Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock and bacterial pneumonia. Crit Care Med 25: 607-613
34. Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM (1996) Tumor necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 347: 1151-1155
35. Satoh M, Nakumura M, Tamura G, Makita S, Segawa I, Tashiro A, Satodate R, Hiramori K (1997) Inducible nitric oxide synthase and tumor necrosis factor-alpha in myocardium in human dilated cardiomyopathy. J Am Coll Cardiol 29: 716-724
36. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O (1995) Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92: 1479-1486
37. Diez FL, Nieto ML, Fernandez-Gallardo S, Gijon MA, Crespo MS (1989) Occupancy of platelet receptors for platelet-activating factor in patients with septicaemia. J Clin Invest 83: 1733-1740
38. Kenzora JL, Perez JE, Bergmann SR, Lange LG (1984) Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs. J Clin Invest 74: 1193-1203
39. Yamanaka S, Iwao H, Yukimura T, Kim S, Miura K (1993) Effect of the platelet-activating factor antagonist. TCV-309, and the cyclo-oxygenase inhibitor, ibuprofen, on the haemodynamic changes in canine experimental endotoxic shock. Br J Pharmacol 110: 1501-1507
40. Herbertson MJ, Werner HA, Walley KR (1997) Platelet-activating factor antagonism improves ventricular contractility in endotoxaemia. Crit Care Med 25: 221-226
41. Liu SF, Newton R, Evans TW, Barnes PJ (1996) Differential regulation of cyclo-oxygenasc-1 and cyclo-oxygenase-2 gene expression by lipopolysaccharide treatment in the rat. Clin Sci 90: 301-306
42. Herbertson MJ, Werner HA, Studer W, Russell JA, Walley KR (1996) Decreased left ventricular contractility during porcine endotoxcmia is not prevented by ibuprofen. Crit Care Med 24: 815-819
43. Bernard GR, Wheeler AP, Ibuprofen in Sepsis Study Group (1997) The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 336: 912-918
44. Shah AM, Mebazaa A, Wetzel RC, Lakatta EG (1994) Novel cardiac myofilament desensitizing factor released by endocardial and vascular endothelial cells. Circulation 89: 2492-2497
45. Pepper CB, Lang D, Lewis MJ, Shah AM (1995) Endothelial inhibition of myofilament calcium response in intact cardiac myocytes. Am J Physiol 269: H1538-H1544
46. Shah AM, Mebazaa A, Yang Z-K, Cuda G, Lankford EB, Pepper CB, Sollott SJ, Sellers JR, Robotham JL, Lakatta EG (1997) Inhibition of myocardial cross-bridge cycling by hypoxic endothelial cells. A potential mechanism for matching oxygen supply and demand? Circ Res 80: 688-698
47. Kelly RA, Balligand J-L, Smith TW (1996) Nitric oxide and cardiac contractile function. Circ Res 79: 363-380
48. 2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol 105: 575-580
49. Balligand J-L, Ungureanu-Longrois D, Simmons WW, Kobzik L, Lowenstein CJ, Lamas S, Kelly RA, Smith TW, Michel T (1995) Induction of NO synthase in rat cardiac microvascular endothelial cells by IL-1 β and IFN-γ. Am J Physiol 268: H1293-H1303
50. Grocott-Mason RM, Anning P, Evans HG, Lewis MJ, Shah AM (1994) Modulation of left ventricular relaxation in isolated ejecting guinea pig heart by endogenous nitric oxide. Am J Physiol 267: H1804-H1813
51. Paulus WJ, Vantrimpont PJ, Shah AM (1994) Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in man. Circulation 89: 2070-2078
52. Paulus WJ, Vantrimpont PJ, Shah AM (1995) Paracrine coronary endothelial control of left ventricular function in humans. Circulation 92: 2119-2126
53. Balligand J-L, Kohzik L, Han X, Kaye DM, Belhassen L, O'Hara DS, Kelly RA, Smith TW, Michel T (1995) Nitric oxide-dependent parasympathetic signaling is due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac myocytes. J Biol Chem 270: 14582-14586
54. Bartunek J, Shah AM, Vanderheyden M, Paulus WJ (1997) Dobutamine enhances cardiodepressant effects of receptor-mediated coronary endothelial stimulation. Ciruclation 95: 90-96
55. Prendergast BD, Sagach VF, Shah AM (1997) Endogenous nitric oxide augments the Frank-Starling response in the isolated heart. Circulation 96: 1320-1329
56. Finkel MS, Oddis CV, Mayer H, Hattler BG, Simmons RL (1995) Nitric oxide synthase inhibitor alters papillary muscle force-frequency relationship. J Pharmacol Exp Ther 272: 945-952
57. Han X, Shimoni Y, Giles WR (1994) An obligatory role for nitric oxide in autonomic control of mammalian heart rate. J Physiol 476: 309-314
58. f. Circ Res 81: 60-68
59. Stamler JS, Singel DJ, Loscalzo J (1992) Biochemistry of nitric oxide and its redox-activated forms. Science 258: 1898-1902
60. Shah AM, Spurgeon H, Sollott SJ, Talo A, Lakatta EG (1994) 8-bromo cyclic GMP reduces the myofilament response to calcium in intact cardiac myocytes. Circ Res 74: 970-978
61. Lincoln TM, Cornwell TL (1993) Intracellular cyclic GMP receptor proteins. FASEB J 7: 328-338
62. Brady AJB, Poole-Wilson PA, Harding SE, Warren JB (1992) Nitric oxide within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol 263: H1963-H1966
63. Luss H, Watkins SC, Freeswick PD, Imro AK, Nussler AK, Billiau TR, Simmons RL, del Nido PJ, McGowen FX Jr (1995) Characterization of inducible nitric oxide synthase expression in endotoxemic rat cardiac myocytes in vivo and following cytokine exposure in vitro. J Mol Cell Cardiol 27: 2015-2029
64. Balligand J-L, Ungureanu D, Kelly RA, Kobzik L, Pimentai D, Michel T, Smith TW (1993) Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest 91: 2314-2319
65. Evans HG, Lewis MJ, Shah AM (1993) Interleukin-1 β modulates mycardial contraction via dexamethasone-sensitive production of nitric oxide. Cardiovasc Res 27: 1486-1490
66. Fishman D, Liaudet L, Lazor R, Perret CH, Feihl F (1997) L-canavanine, an inhibitor of inducible nitric oxide synthase, improves venous return in endotoxemic rats. Crit Care Med 25: 469-475
67. MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, Stevens K, Xie Q, Sokol K, Hutchinson N, Chen H, Mudgett JS (1995) Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 81: 641-650
68. Keller RS, Jones JJ, Kim KF, Myers PR, Adams HR, Parker JL, Rubin LJ (1995) Endotoxin-induced myocardial dysfunction: is there a role for nitric oxide. Shock 4: 338-344
69. Klabunde RE, Coston AF (1995) Nitric oxide synthase inhibition does not prevent cardiac depression in endotoxic shock. Shock 3: 73-78
70. Simmons WW, Ungureanu-Longrois D, Smith GK, Smith TW, Kelly RA (1996) Glucocorticoids regulate inducible nitric oxide synthase (NOS2) by inhibiting tetrahydrobiopterin synthesis and L-arginine transport. J Biol Chem 271: 23928-23937
71. Nathan C (1995) Natural resistance and nitric oxide. Cell 82: 873-876
72. Oddis CV, Finkel MS (1995) Cytokine-stimulated nitric oxide production inhibits mitochondrial activity in cardiac myocytes. Biochem Biophys Res Comm 213: 1002-1009
73. Xie YW, Shen W, Zhao G, Xu X, Wolin MS, Hintze T (1996) Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro. Circ Res 79: 381-387
74. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87: 1620-1624
75. Pinsky DJ, Cai B, Yang X, Rodriguez C, Sciacca RR, Cannon PJ (1995) The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor β. J Clin Invest 95: 677-685
76. Ziegler EJ, Fisher CJ, Sprung CL, HA-1A Sepsis Study Group (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin - a randomized, double-blind, placebo-controlled trial. N Engl J Med 324: 429-436
77. Greenman RL, Schein RM, Martin MA, XOMA Sepsis Study Group (1991) A controlled clinical trial of E5 murine monocloncal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266: 1097-1102
78. Exley AR, Cohen J, Buurman W, Owen R, Hanson G, Lumley J, Aulakh JM, Bodmer M, Riddell A, Stephens S, Perry M (1990) Monoclonal antibody to TNF in severe septic shock. Lancet 353: 1275-1277
79. Vincent JL, Bakker J, Marcecaux G, Schandene L, Kahn RJ, Dupont E (1992) Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study. Chest 101: 810-815
80. Reinhart K, Wiegand-Lohnert C, Grimminger F, Kaul M, Withington S, MAK 195F Sepsis Study Group (1996) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomised, placebo-controlled, dose ranging study. Crit Care Med 24: 733-742
81. Cohen J, Carlet J, INTERSEPT Study Group (1996) An international multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 24: 1431-1440
82. Dhainaut J-F, Tenaillon A, Le Tulzo Y, BN 52021 Sepsis Study Group (1994) Platelet-activating receptor antagonist BN 52021 in the treatment of severe sepsis: a randomised, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 22: 1720-1728
83. Fisher CJ, Agosti JM; Opal SM, Soluble TNF Receptor Sepsis Study Group (1996) Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 334: 1697-1702
84. Bone RC, Fisher CJ, Clemmer TP. Methylprednisolone Severe Sepsis Study Group (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317: 653-658
85. Lorente JA, Landis L, de Pablo R, Renes E, Liste D (1993) L-arginine pathway in the sepsis syndrome. Crit Care Med 21: 1287-1295
86. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P (1994) Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 28: 34-39
87. Preiser J-C, Lejeune P, Roman A, Carlier E, Backer DD, Leeman M, Kahn R, Vincent J-L (1995) Methylene blue administration in septic shock: a clinical trial. Crit Care Med 23: 259-264
88. Kiehl MG, Ostermann H, Meyer J, Kienast J (1997) Nitric oxide synthase inhibition by L-NAME in Ieukocytopaenic patients with severe septic shock. Intensive Care Med 23: 561-566